Interações medicamentosas
Efgartigimod / hyaluronidase sc + Nivolumab
Gravidade: Moderada
Efgartigimod / hyaluronidase sc and Nivolumab: moderate interaction.
Última atualização
Para profissionais de saúde — apenas referência. Esta página é um resumo breve, não é aconselhamento médico nem substitui a bula oficial ou o julgamento clínico. Verifique sempre antes de prescrever ou dispensar.
O conteúdo clínico desta página está disponível apenas em inglês.
Resumo
Subcutaneous efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
O que esta interação significa em palavras simples
Efgartigimod / hyaluronidase sc and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Por que acontece
Efgartigimod blocks FcRn-mediated IgG recycling, which may accelerate catabolism of IgG-based nivolumab.
O que fazer
Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
O que perguntar ao farmacêutico
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Para assinantes do Pro+
Desbloqueie a página completa
Crie uma conta e comece um teste do Pro+ para desbloquear a orientação completa de conduta para Efgartigimod / hyaluronidase sc e Nivolumab, as notas adicionais, os detalhes da evidência e o verificador de interações para uma prescrição completa.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Experimente o Pro+ grátis por 7 dias na web. Sem cartão.
Outras interações de Nivolumab
- Nivolumab + Thalidomide Grave
- Dexamethasone-tobramycin + Nivolumab Moderada
- Dexamethasone + Nivolumab Moderada
- Efgartigimod alfa + Nivolumab Moderada
- Nivolumab + Ponesimod Moderada
- Nivolumab + Rozanolixizumab Moderada
Perguntas frequentes
Can I take Efgartigimod / hyaluronidase sc with Nivolumab?
MediHelp rates the interaction as moderate. Efgartigimod / hyaluronidase sc and Nivolumab can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Subcutaneous efgartigimod blocks the neonatal Fc receptor, which normally protects IgG antibodies from degradation. Nivolumab is an IgG4 antibody, so its clearance could increase and exposure fall, potentially weakening antitumor effect. The clinical significance is uncertain.
How serious is the interaction between Efgartigimod / hyaluronidase sc and Nivolumab?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining where possible, or monitor tumor response closely if efgartigimod is necessary. Involve oncology and neurology specialists in weighing alternatives.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
Monografias completas, posologia e verificador de interações no app MediHelp
Abra a referência completa, verifique interações entre vários medicamentos e use as ferramentas de posologia no app MediHelp.
